Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

457.07 +7.51 (+1.67%)
Streaming Delayed Price Updated: 2:12 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 646,457
Open 449.00
Bid (Size) 456.19 (4)
Ask (Size) 457.62 (1)
Prev. Close 449.56
Today's Range 441.22 - 457.57
52wk Range 205.87 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion. 
Via Benzinga
Topics Law Enforcement
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings
Alnylam's Q3 2025 earnings crushed estimates with a $2.90 EPS and 149% revenue growth, driven by AMVUTTRA, despite a pre-market stock dip. 
Via Chartmill

Performance

YTD
+95.6%
+95.6%
1 Month
+0.2%
+0.2%
3 Month
+16.5%
+16.5%
6 Month
+79.2%
+79.2%
1 Year
+62.4%
+62.4%

More News

Read More
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
Via Investor's Business Daily
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For October 30, 2025
Via Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Via Benzinga
Topics Economy
Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview
Via Benzinga
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Via Benzinga
Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest
Via Benzinga
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout
Via Chartmill
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Via Benzinga
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
Via MarketMinute
Topics Artificial Intelligence Economy Government
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
Via Investor's Business Daily
Topics ETFs Government World Trade
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Via Benzinga
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
Via Benzinga
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 457.07
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 10/31/25 02:12 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 54.32B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 54B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.